1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Endometrial Cancer - Drugs In Development, 2022, provides an overview of the Endometrial Cancer (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Endometrial cancer is cancer that starts in the endometrium, the lining of the uterus (womb). Endometrial cancer is the most common type of uterine cancer. Although the exact cause of endometrial cancer is unknown, increased levels of estrogen appear to play a role. Estrogen helps stimulate the buildup of the lining of the uterus. Symptoms of endometrial cancer include abnormal bleeding from the vagina, including bleeding between periods or spotting/bleeding after menopause, extremely long, heavy or frequent episodes of vaginal bleeding after age 40, lower abdominal pain or pelvic cramping and thin white or clear vaginal discharge after menopause.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Endometrial Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Endometrial Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Endometrial Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Endometrial Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 11, 147, 100, 8, 29 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 4, 7 and 3 molecules, respectively.
Endometrial Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Endometrial Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Endometrial Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Endometrial Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Endometrial Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Endometrial Cancer (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Endometrial Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Endometrial Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Endometrial Cancer - Overview
- Endometrial Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Endometrial Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Endometrial Cancer - Companies Involved in Therapeutics Development
- Endometrial Cancer - Drug Profiles
- Endometrial Cancer - Dormant Projects
- Endometrial Cancer - Discontinued Products
- Endometrial Cancer - Product Development Milestones
- Featured News & Press Releases
- Sep 29, 2022: Imvax presents new data on personalized whole-tumor derived immunotherapeutic platform at 2022 International Cancer Immunotherapy Conference
- Sep 13, 2022: Eisai presents new data on lenvatinib from its oncology portfolio and pipeline at ESMO Congress 2022
- Aug 17, 2022: Mersana begins dosing in Phase I solid tumour therapy trial
- Aug 03, 2022: ProfoundBio receives FDA "Study May Proceed" Letter for PRO1184, a Folate Receptor Alpha-Directed ADC with a Topoisomerase 1 inhibitor payload, and welcomes Naomi Hunder, M.D., as Chief Medical Officer
- Jul 14, 2022: Theratechnologies provides update on the dose escalation portion of Fast Track designated TH1902 first-in-human study in advanced resistant malignancies
- Jul 12, 2022: Leap Therapeutics announces initiation of new DKN-01 clinical trials in gastric cancer, colorectal cancer and endometrial cancer
- Jun 27, 2022: Harbour BioMed announces IND clearance for B7H4x4-1BB bispecific antibody by the U.S. Food and Drug Administration
- Jun 03, 2022: Made-in-Singapore cancer drug ETC-159 advances in clinical trials
- May 26, 2022: Karyopharm to present new Selinexor data at the 2022 American Society of Clinical Oncology Annual Meeting
- May 11, 2022: Amber Specialty Pharmacy added to Eisai’s LENVIMA Network
- May 05, 2022: Context Therapeutics announces poster presentation at the upcoming 2022 ASCO Annual Meeting
- Apr 28, 2022: Clovis Oncology highlights Rubraca data to be presented at 2022 ASCO Annual Meeting
- Apr 27, 2022: Karyopharm announces selinexor data to be presented at the 2022 American Society of Clinical Oncology Annual Meeting
- Apr 08, 2022: Sutro Biopharma presents nonclinical data for antibody-drug conjugate STRO-002 at the AACR Annual Meeting 2022
- Apr 05, 2022: Nurix Therapeutics doses first patient in phase 1 clinical trial of DeTIL-0255, a drug-enhanced cell therapy for the treatment of patients with solid tumors
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Endometrial Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Endometrial Cancer - Dormant Projects, 2022
- Endometrial Cancer - Discontinued Products, 2022
- Number of Products under Development for Endometrial Cancer, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- A28 Therapeutics Inc
- Aadi Bioscience Inc
- Ability Pharmaceuticals SL
- ABL Bio Inc
- Abpro Corp
- Acrivon Therapeutics Inc
- Adaptimmune Therapeutics Plc
- ADC Therapeutics SA
- Adlai Nortye Biopharma Co Ltd
- Advenchen Laboratories LLC
- Agenus Inc
- Akeso Inc
- Alaunos Therapeutics Inc
- Alkermes Plc
- Allarity Therapeutics Inc
- Alligator Bioscience AB
- Almac Discovery Ltd
- Alphamab Oncology
- ALX Oncology Holdings Inc
- Ambrx Biopharma Inc
- Amgen Inc
- Aminex Therapeutics Inc
- Amphivena Therapeutics Inc
- Apexian Pharmaceuticals Inc
- Apexigen Inc
- Apollomics Inc
- Arch Oncology Inc
- Arcus Biosciences Inc
- Ascenta Therapeutics Inc
- AstraZeneca Plc
- Bantam Pharmaceutical LLC
- Basilea Pharmaceutica Ltd
- Bavarian Nordic AS
- Bayer AG
- BeiGene Ltd
- Beijing Neoantigen Biotechnology Co Ltd
- Bellicum Pharmaceuticals Inc
- Bicycle Therapeutics Plc
- Bio-Path Holdings Inc
- BioAtla Inc
- BioMed Valley Discoveries Inc
- BioNTech SE
- Biosion Inc
- Biosplice Therapeutics Inc
- Biotheus Inc
- Blueprint Medicines Corp
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Byondis BV
- Calithera Biosciences Inc
- CanBas Co Ltd
- Carrick Therapeutics Ltd
- Celon Pharma SA
- Checkpoint Therapeutics Inc
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Chimerix Inc
- Clovis Oncology Inc
- Coherent Biopharma
- Compugen Ltd
- Context Therapeutics Inc
- Corvus Pharmaceuticals Inc
- Cotinga Pharmaceuticals Inc
- CStone Pharmaceuticals Co Ltd
- Cue Biopharma Inc
- Cyclacel Pharmaceuticals Inc
- Daiichi Sankyo Co Ltd
- Dragonboat Biopharmaceutical (Shanghai) Co Ltd
- Eisai Co Ltd
- Eli Lilly and Co
- Ella Therapeutics Ltd
- Elucida Oncology Inc
- ENB Therapeutics LLC
- EpimAb Biotherapeutics Inc
- Esperas Pharma Inc
- EstryX Pharma Ltd
- Exelixis Inc
- F-star Therapeutics Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Fujifilm Holdings Corp
- Fusion Pharmaceuticals Inc
- Genelux Corp
- Genentech USA Inc
- Genmab AS
- Gilead Sciences Inc
- Gradalis Inc
- Greenfire Bio LLC
- GSK plc
- Guangzhou Yinming Biomedical Technology Co Ltd
- Hanmi Pharmaceuticals Co Ltd
- Harbin Gloria Pharmaceuticals Co Ltd
- Harbour BioMed (Guangzhou) Co Ltd
- Horizon Therapeutics Plc
- Huabo Biopharm (Shanghai) Co Ltd
- Hummingbird Bioscience Pte Ltd
- Hutchison MediPharma Ltd
- Idience Co Ltd
- Immatics NV
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- Immunocore Limited
- ImmunoGen Inc
- Immvira Co Ltd
- IMPACT Therapeutics Inc
- Imunon Inc
- Imvax Inc
- Incyte Corp
- Innate Pharma SA
- Innovent Biologics Inc
- Inspirna Inc
- Instil Bio Inc
- iTeos Therapeutics Inc
- Jiangsu Hengrui Medicine Co Ltd
- Johnson & Johnson
- Karyopharm Therapeutics Inc
- Komipharm International Co Ltd
- L&L Biopharma Co Ltd
- Laekna Therapeutics Shanghai Co Ltd
- Leap Therapeutics Inc
- LegoChem Biosciences Inc
- Light Chain Bioscience
- MedGene Therapeutics Inc
- Merck & Co Inc
- Merck KGaA
- Mereo Biopharma Group Plc
- Mersana Therapeutics Inc
- Millennium Pharmaceuticals Inc
- Mirati Therapeutics Inc
- Molecular Partners AG
- Molecular Templates Inc
- MorphoSys AG
- NeoTX Therapeutics Ltd
- Netris Pharma SAS
- NextCure Inc
- Northlake International LLC
- Novartis AG
- Novita Pharmaceuticals Inc
- Nurix Therapeutics Inc
- Nuvation Bio Inc
- Nuvectis Pharma Inc
- Olema Pharmaceuticals Inc
- OncoQuest Inc
- OncoResponse Inc
- OncXerna Therapeutics Inc
- Ono Pharmaceutical Co Ltd
- Orano Med LLC
- Otsuka Pharmaceutical Co Ltd
- Pano Therapeutics Inc
- Pfizer Inc
- Pharma Mar SA
- Pieris Pharmaceuticals Inc
- Pionyr Immunotherapeutics Inc
- Portage Biotech Inc
- Precision Biologics Inc
- Prelude Therapeutics Inc
- PRISM Pharma Co Ltd
- ProfoundBio Suzhou Co Ltd
- PsiOxus Therapeutics Ltd
- PTC Therapeutics Inc
- Puma Biotechnology Inc
- Qurient Co Ltd
- RemeGen Co Ltd
- Repare Therapeutics Inc
- Rhizen Pharmaceuticals SA
- Salarius Pharmaceuticals Inc
- Sanofi
- Seagen Inc
- SELLAS Life Sciences Group Inc
- Shandong Boan Biotechnology Co Ltd
- Shandong New Time Pharmaceutical Co Ltd
- Shanghai Escugen Biotechnology Co Ltd
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
- Shanghai Haihe Biopharma Co Ltd
- Shanghai Jiatan Pharmaceutical Technology Co Ltd
- Shanghai Junshi Bioscience Co Ltd
- Shanghai Yingli Pharmaceutical Co Ltd
- Shenzhen Evergreen Therapeutics Co Ltd
- Sihuan Pharmaceutical Holdings Group Ltd
- Simcha Therapeutics Inc
- Sino Biopharmaceutical Ltd
- Sorrento Therapeutics Inc
- Splash Pharmaceuticals Inc
- SpringWorks Therapeutics Inc
- Sutro Biopharma Inc
- Suzhou Maximum Bio-tech Co Ltd
- Suzhou Neupharma Co Ltd
- Suzhou Zelgen Biopharmaceutical Co Ltd
- SynOx Therapeutics Ltd
- Taiho Pharmaceutical Co Ltd
- TCR Cure Biopharma Technology Co Ltd
- Tempest Therapeutics Inc
- Theratechnologies Inc
- TORL Biotherapeutics LLC
- Treadwell Therapeutics Inc
- Triumvira Immunologics Inc
- Turning Point Therapeutics Inc
- Tyra Biosciences Inc
- Verastem Inc
- Vincerx Pharma Inc
- Vyriad Inc
- Wigen Biomedicine Technology (Shanghai) Co Ltd
- Xencor Inc
- Xynomic Pharmaceuticals Holdings Inc
- Y-Biologics Inc
- Zymeworks Inc
